

Ref. No. : JPL/CS/2088/2024

Date: 28<sup>th</sup> May, 2024

To  
BSE Ltd.,  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.  
Script Code: 524731

Sub.: **Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015:  
Change in Directors**

Reg.: **Outcome of Board Meeting held today, i.e. 28<sup>th</sup> May, 2024.**

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015 (SEBI-LODR), we would like to inform you that the Board of Directors of the Company at its meeting held today, on 28<sup>th</sup> May, 2024, inter-alia has approved / recommended the followings:

1. The re-appointment of Smt. Hina Ravindra. Mehta (DIN: 08719453) as the Non-executive and Independent Director on the Board of the Company for the second term of five consecutive years from 27<sup>th</sup> March, 2025 to 26<sup>th</sup> March, 2030.
2. The appointment of Shri Krishnan Subharaman (DIN: 01518995) as an Additional Director in the category of Non-Executive - Independent Director, on the Board of the Company for a term of three consecutive years with effect from 28<sup>th</sup> May, 2024 to 27<sup>th</sup> May, 2027.
3. The appointment of Shri Pankaj Arun Dantwala (DIN: 02158836) as an Additional Director in the category of Non-Executive - Independent Director, on the Board of the Company for a term of three consecutive years with effect from 28<sup>th</sup> May, 2024 to 27<sup>th</sup> May, 2027.
4. To take on record the retirement three Non-executive and Independent Directors viz. Shri Bharat V. Bhate (DIN: 00112361), Shri Rameshchandra J. Vora (DIN: 00112446) and Shri Arun R. Raskapurwala (DIN: 00143983), from the Board of the Company, consequent to completion of their second and last term of five years each, with effect from the end of business hours on 29<sup>th</sup> May, 2024.

The requisite details of the directors in terms of Regulation 30 of the SEBI- LODR and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023, are provided in Annexure – '1'.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,  
For Jenburkt Pharmaceuticals Limited,

(ASHISH R. SHAH)  
Company Secretary and Compliance Officer

**Annexure 1**
**Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July , 2023.**

- I. Re-appointment of Smt. Hina R. Mehta (DIN: 08719453) as the Non-executive and Independent Director for the second term :

Sr. No	Particulars	Details
1	Reason for change viz. appointment	Re-Appointment: Based on the recommendations of Nomination and Remuneration Committee Smt. Hina R. Mehta is Re-appointed as Non-Executive and Independent Director of the Company for the second term of five consecutive years effective from 27 <sup>th</sup> March, 2025 to 26 <sup>th</sup> March, 2030, subject to the shareholders' approval, at the ensuing 39 <sup>th</sup> Annual General Meeting.
2	Date of appointment/re-appointment/ (as applicable) & term of appointment/re-appointment;	27 <sup>th</sup> March, 2025  Term of Re-appointment: for the second term of five consecutive years effective from 27 <sup>th</sup> March, 2025 to 26 <sup>th</sup> March, 2030
3	Brief profile (in case of appointment);	Mrs. Hina Ravindra Mehta, aged 61 years, is a Chartered Accountant from Mumbai. She has also done certification Course of Information System Audit (ISA) from the institute of Chartered Accountants of India.  She is an accomplished, resourceful professional with 35 plus years of exhaustive experience in all activities related to accounts, finance, taxation, and Company law matters. She has a blend of expertise in corporate accounts, finance, statutory compliance coupled with profound people management skills; excellent interpersonal, analytical & negotiation skills. She has a rich experience of working at various senior management positions in varied industries in the areas of accounts, finance, taxation, Company law matters, strategy planning, regulatory compliances and liaisons with government departments.
4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any Director / Key Managerial Personnel of the Company
5	Information as required, In compliance with BSE's Circular No. LIST/COMP/ 14/2018-19 dated 20 <sup>th</sup> June , 2018.	As per the confirmation received from Smt. Hina R. Mehta, she has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority. She has further confirmed that she does not hold any Equity shares of Jenburkt pharmaceuticals Limited as on date.

II. Appointment of Shri Krishnan Subharaman (DIN: 01518995) as an Additional Director in the Category of Non-Executive and Independent Director:

Sr. No	Particulars	Details
1	Reason for change viz. appointment	Appointment: Due to the retirement of three existing Non-Executive And Independent Directors upon completion of their second and final terms on 29 <sup>th</sup> May, 2024 and based on the recommendation of Nomination and Remuneration Committee, Shri Krishnan Subharaman is appointed as an Additional Director in the category of Non-Executive and Independent Director of the Company for the first term of three consecutive years effective from 28 <sup>th</sup> May, 2024 to 27 <sup>th</sup> May, 2027, subject to the Shareholders' approval, at the ensuing 39 <sup>th</sup> Annual General Meeting.
2	Date of appointment/re-appointment/(as applicable) & term of appointment/re-appointment;	28 <sup>th</sup> May, 2024  Term of appointment: for the first term of three consecutive years effective from 28 <sup>th</sup> May, 2024 to 27 <sup>th</sup> May, 2027
3	Brief profile (in case of appointment);	Shri Krishnan Subharaman, aged 63 years, is a Fellow Member of the Institute of Company Secretaries of India [FCS] and has done his M. Com and a Law Graduation from Bombay University. He has also done post graduate studies in Intellectual Property Rights specialising in Patents. Further, he has completed a Senior Management Development Program from IIM Ahmedabad.  He has worked in reputed organisations; more particularly in the Pharmaceuticals, Fertilizers and Chemicals Industries for over 30 years. He had long association of over 15 years with Unichem Laboratories Ltd. as their Vice President Legal & Company Secretary. He was also employed with Pfizer Limited as their Director Corporate Services and Company Secretary for 3 years. He retired as Executive Vice President Legal & Company Secretary from Deepak Fertilisers and Petrochemicals Limited in November 2020. His areas of core competence includes Corporate Laws, Accounts and Finance, Fund Raising through various debt or convertible instruments, Corporate actions like IPOs, Right Issues, Bonus Issues, Split, Buyback, Corporate Litigations, Intellectual Property Rights, Corporate Governance, Legal Compliance, Insurance. Presently, He is Practicing as a Company Secretary and Corporate Advisor on Legal and Corporate Governance matters.
4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any Director / Key Managerial Personnel of the Company.

5	Information as required, In compliance with BSE's Circular No. LIST/COMP/ 14/2018-19 dated 20 <sup>th</sup> June , 2018.	As per the confirmation received from Shri Krishnan Subharaman, he has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority. He has further confirmed that he does not hold any Equity shares of Jenburkt Pharmaceuticals Limited as on date.
---	--	--

III. Appointment of Shri Pankaj Arun Dantwala (DIN: 02158836) as an Additional Director in the Category of Non-Executive and Independent Director:

Sr. No	Particulars	Details
1	Reason for change viz. Appointment	Appointment: Due to the retirement of three existing Non-Executive And Independent Directors upon completion of their second and final terms on 29 <sup>th</sup> May, 2024 and based on the recommendations of Nomination and Remuneration Committee Shri Pankaj Arun Dantwala is appointed as an Additional Director in the category of Non-Executive and Independent Director of the Company for the first term of three consecutive years effective from 28 <sup>th</sup> May, 2024 to 27 <sup>th</sup> May, 2027, subject to the shareholders' approval, at the ensuing 39 <sup>th</sup> Annual General Meeting.
2	Date of appointment/re-appointment (as applicable) & term of appointment/re-appointment;	28 <sup>th</sup> May, 2024  Term of appointment : for the first term of three consecutive years effective from 28 <sup>th</sup> May, 2024 to 27 <sup>th</sup> May, 2027
3	Brief profile (in case of appointment);	<p>Shri Pankaj Arun Dantwala, aged 65 years, is a Associate Member of The Institute of Chartered Accountants of India [ACA]. He is a Commerce Graduate from Mumbai University and has also done Diploma in Information Systems Audit (DISA) and Diploma in Insurance and Risk Management (DIRM) form The Institute of Chartered Accountants of India.</p> <p>Shri Pankaj Arun Dantwala is at present working as a Chief Financial Officer at Clover Technologies Pvt Ltd., a Clover Group Entity. He has over 40 years of experience in the areas of Accounts, Audit, Tax and Finance. He has held various key positions in reputable organizations, showcasing his expertise in finance, taxation, risk management, and consultancy. His past experiences include roles such as General Manager (GM) of Information Systems, Risk Management &amp; Taxation at Hinduja TMT Ltd., GM of Accounts at Aasia Management &amp; Consultancy Pvt Ltd. (a Hinduja Group entity), and Senior Manager Accounts at FDC Ltd. He has also served in managerial capacities at Ocean Harvest Fisheries Pvt Ltd., Bajaj Electricals Ltd., Navnitlal &amp; Co., and Orion Management Group, contributing his financial acumen across diverse industries including finance, service, pharma, seafood, consumer durables, textiles, and management consulting. He is on the Board of four private companies.</p>

4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any Director / Key Managerial Personnel of the Company.
5	Information as required, In compliance with BSE's Circular No. LIST/COMP/ 14/2018-19 dated 20 <sup>th</sup> June, 2018.	As per the confirmation received from Shri Pankaj Arun Dantwala, he has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority. He has further confirmed that he does not hold any Equity shares of Jenburkt Pharmaceuticals Limited as on date.

IV. Cessation of second term of Shri Bharat V. Bhate (DIN: 00112361), Shri Rameshchandra J. Vora (DIN: 00112446) and Shri Arun R. Raskapurwala (DIN: 00143983), Non-executive and Independent Directors of the Company:

Sr. No	Particulars	Details
1	Reason for change viz. Cessation	Retirement due to completion of 02 <sup>nd</sup> term as a non-executive and Independent Director.
2	Date of cessation (as applicable)	The second term of 5(five) years of Shri Bharat V. Bhate (DIN: 00112361), Shri Rameshchandra J. Vora (DIN: 00112446) and Shri Arun R. Raskapurwala (DIN: 00143983), as the Non-executive and Independent Directors of the Company with effect from 29 <sup>th</sup> May, 2024.
3	Brief profile (in case of appointment);	NA
4	Disclosure of relationships between directors (in case of appointment of a director).	NA

For Jenburkt Pharmaceuticals Limited,

(ASHISH R. SHAH)  
Company Secretary and Compliance Officer